文献速递系统性红斑狼疮

一项在位于中国、日本和韩国的系统性红斑狼疮患者中开展的贝利尤单抗关键性III期随机安慰剂对照研究

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
PubMed 文献 · Ann Rheum Dis · 2018-01-02

这项III期多中心随机双盲安慰剂对照研究纳入中国、日本和韩国677例SLE患者,按2:1随机接受静脉贝利尤单抗10 mg/kg或安慰剂联合标准治疗,每4周一次至第48周。第52周贝利尤单抗组SRI4应答率53.8% vs 安慰剂组40.1%(OR 1.99,95%CI 1.40-2.82,P=0.0001),严重复发风险降低50%(P=0.0004),基线泼尼松剂量>7.5 mg/day者激素用量显著减少(P=0.0228),不良事件发生率两组相似。

要点

  • 第52周SRI4应答率贝利尤单抗组53.8% vs 安慰剂组40.1%(OR 1.99,95%CI 1.40-2.82,P=0.0001)。
  • 贝利尤单抗组严重复发风险较安慰剂组降低50%(P=0.0004)。
  • 基线泼尼松剂量>7.5 mg/day者中贝利尤单抗组激素用量显著减少(P=0.0228),不良事件发生率两组相似。

核心结论

  • 在东北亚SLE患者中,贝利尤单抗显著改善疾病活动度并减少泼尼松用量,未出现新的安全性问题。

研究设计与样本

  • III期多中心随机双盲安慰剂对照研究(BEL113750;NCT01345253),在中国、日本和韩国49个中心开展(2011年5月至2015年9月)。
  • SLE患者按2:1随机接受静脉贝利尤单抗10 mg/kg或安慰剂联合标准治疗,每4周一次至第48周。
  • 改良意向治疗人群共677例(贝利尤单抗组n=451,安慰剂组n=226)。

主要发现

  • 第52周SRI4应答率贝利尤单抗组53.8% vs 安慰剂组40.1%(OR 1.99,95%CI 1.40-2.82,P=0.0001)。
  • SELENA-SLEDAI评分较基线降低≥4分的患者百分比和SRI7应答率贝利尤单抗组均显著高于安慰剂组。
  • 贝利尤单抗组发生严重复发的风险较安慰剂组降低50%(P=0.0004)。
  • 基线泼尼松剂量>7.5 mg/day的患者中,贝利尤单抗组激素用量显著减少(P=0.0228)。
  • 不良事件发生率两组相似。

关键数值与推荐

  • 主要终点为第52周SRI4应答率。
  • 次要终点包括SELENA-SLEDAI评分降低≥4分的患者百分比、SRI7应答率、首次严重复发时间、泼尼松(或等效剂量)≤7.5 mg/day和/或较基线降低50%的天数。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous belimumab plus standard of care (SoC) is approved in the USA and Europe for treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). METHODS: This phase III, multicentre, randomised, double-blind, placebo-controlled study (BEL113750; NCT01345253) was conducted in 49 centres across China, Japan and South Korea (May 2011-September 2015). Patients with SLE were randomised 2:1 to intravenous belimumab 10 mg/kg or placebo, plus SoC, every 4 weeks until Week 48. The primary endpoint was the SLE Responder Index (SRI) 4 response rate at Week 52. Secondary endpoints were the percentage of patients with ≥4 point reduction in Safety of Oestrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI), SRI7, time to first severe flare and number of days prednisone (or equivalent) dose ≤7.5 mg/day and/or reduced by 50% from baseline. Safety was assessed. RESULTS: The modified intent-to-treat population included 677 patients (belimumab n=451, placebo n=226). At Week 52, the SRI4 response rate was higher with belimumab versus placebo (53.8% vs 40.1%; OR: 1.99 (95% CI: 1.40, 2.82; P=0.0001)). The percentages of patients with a ≥4 point reduction in SELENA-SLEDAI and an SRI7 response were significantly greater for belimumab versus placebo. Patients in the belimumab group had a 50% lower risk of experiencing a severe flare than those receiving placebo (P=0.0004). In patients with baseline prednisone dose >7.5 mg/day, there was a significant reduction in steroid use favouring belimumab (P=0.0228). The incidence of adverse events was similar between groups. CONCLUSIONS: In patients with SLE from North East Asia, belimumab significantly improved disease activity, while reducing prednisone use, with no new safety issues.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Zhang F, Bae SC, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018. PMID: 29295825. doi:10.1136/annrheumdis-2017-211631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。